Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

SFDA To Release Measures For Drug Reevaluation In 2009

This article was originally published in PharmAsia News

Executive Summary

China's State FDA recently disclosed that administrative measures for drug reevaluation are expected to be issued this year. Drug authorities will analyze drug safety based on monitoring reports and research data of drug adverse incidents, then take appropriate measures to control risks. With special focus on TCM injections, the evaluation will reexamine injections' safety, production techniques and procedures. SFDA has compiled a blacklist based on adverse incident reports in recent years; drug manufacturers will have their production licenses revoked once unaccountable adverse incidents are uncovered. In 2008, Chinese patent medicine was the only drug category which decreased in export volume. Experts point out that the only solution for the sector is to upgrade its techniques. (Click here for more - Chinese Language)

You may also be interested in...



IGBA Criticizes Export Restrictions

National export restrictions on medicines have been slammed by the international off-patent pharmaceutical industry as being “counter-productive” during the coronavirus crisis. The IGBA is instead urging international co-operation and transparency, pointing to a positive example of supply-chain connectivity in the Asia-Pacific region.

Italy’s Dompé Taking Legal Action Over COVID-19 Fake News

Claims circulated on social media that its Cebion supplement could prevent coronavirus has led Italy's Dompé to take legal action.

Stockwatch: Repeating Past Mistakes At AbbVie

AbbVie’s latest, largest acquisition may be cast in a new light as the pandemic throws stock markets into turmoil and commercial prospects up in the air.

UsernamePublicRestriction

Register

SC069792

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel